Fibrinogen receptor antagonist. Specifically inhibits fibrinogen binding to the platelet integrin GPIIb-IIIa which prevents platelet aggregation and subsequent clot formation. Synthetic, disulfide-linked cyclic heptapeptide based on barbourin, a specific GPIIb-IIIa antagonist isolated from venom of the southeastern pigmy rattlesnake, Sistrurus m. barbouri. Contains the Lys-Gly-Asp (KGD) amino acid sequence, a modification of the Arg-Gly-Asp (RGD) recognition site which appears to confer specificity: R. M. Scarborough et al., J. Biol. Chem. 266, 9359 (1991). Design and structure-activity study of integrin antagonists: eidem, ibid. 268, 1066 (1993). Prepn: R. M. Scarborough et al., US 5686570 (1997 to COR Therapeutics). Pharmacology: F. A. Nicolini et al., Circulation 89, 1802 (1994); K. Uthoff et al., ibid. 90, pt 2, II-269 (1994). Clinical trial in patients undergoing percutaneous cardiovascular intervention: IMPACT-II Investigators, Lancet 349, 1422 (1997). Clinical trial in acute coronary syndromes: PURSUIT Trial Investigators, N. Engl. J. Med. 339, 436 (1998).
Antithrombotic.
Antithrombotic